Studies have shown a good concordance between mutations in CTNNB1 and the TERT promoter in HCCs, indicating that inhibitors targeting Wnt/β-catenin and TERT could be beneficial in HCC therapy [83]. Here, CTNNB1 is linked to hepatocellular carcinoma.